Atavistik Bio, Inc.

Atavistik Bio, Inc. , based in the US, specializes in the discovery and development of precision allosteric small molecules, targeting significant unmet medical needs in various diseases, particularly precision oncology and rare diseases. Founded in 2021 and headquartered in Cambridge, US, Atavistik Bio, Inc. focuses on precision medicine through its proprietary drug discovery platform.

The company has completed 2 deals, with the latest funding round occurring on December 19, 2023, raising USD 40. 00 mn from investors including Lux Capital, Nextech, and The Column Group, bringing the total amount raised to USD 40. 00 mn. The CEO, Bryan Stuart, leads the company as it advances its innovative drug discovery efforts.

Atavistik Bio specializes in the discovery and development of precision allosteric small molecules aimed at addressing significant unmet medical needs across various diseases, particularly in precision oncology and rare diseases. The core offering is their proprietary drug discovery platform, known as the AMPS platform, which utilizes a combination of computational and experimental techniques to identify novel allosteric binding pockets. This innovative approach facilitates the design of small molecule therapeutics that can target previously intractable high-value targets. Atavistik Bio's solutions are marketed globally, with a particular focus on regions with high unmet medical needs, such as North America and Europe.

Atavistik Bio generates revenue through partnerships and collaborations with healthcare organizations and pharmaceutical companies that seek to utilize its advanced drug discovery capabilities. Revenue is typically derived from collaboration agreements allowing partners to access Atavistik's proprietary technologies and drug candidates, with potential income from milestone payments and royalties tied to the commercialization of developed therapeutics. The company primarily engages in B2B transactions, selling directly to pharmaceutical companies. In December 2023, Atavistik Bio, Inc.

raised USD 40. 00 mn in venture funding to support its program and technology. In March 2026, Atavistik Bio, Inc. raised USD 40 million in series B funding from RA Capital Management.

The round was part of a larger USD 160 million series B funding. The company plans to utilize this funding to advance its treatment for hereditary hemorrhagic telangiectasia and its targeted therapy program for myeloproliferative neoplasms through clinical proof of concept.